Innovative Neuromodulation Technology Advancement: Wavegate Corporation Secures $26 Million in Series A Funding

Wavegate Corporation is thrilled to announce a successful funding round, raising an impressive $26 million to accelerate the development of its groundbreaking neuromodulation technology, StimuLux™. As a pioneering medical technology company, Wavegate has been at the forefront of advancing treatment options for chronic pain, which affects millions of patients in the United States. The funding will drive key enhancements to the StimuLux™ platform, which is designed to optimize spinal cord stimulation (SCS) therapy. Currently, approximately 68,000 patients annually undergo SCS for pain management, a solution that has been constrained by challenges such as inadequate stimulation due to shifts in spinal cord position during movement. Wavegate's StimuLux™ technology utilizes innovative optical sensing to deliver real-time data on spinal cord positioning, allowing for adaptive neuromodulation that adjusts stimulation intensity dynamically. This promises not only to improve pain relief for patients but also to minimize side effects that can arise from traditional fixed stimulation systems. With this fresh infusion of capital, Wavegate aims to expand its clinical trials and enhance product development, ultimately paving the way for a more effective and personalized approach to managing chronic pain. The capital raised will also bolster Wavegate's effort to bring this revolutionary technology to the market, ensuring that more patients have access to safe, effective, and responsive pain relief options. As we take this leap forward, Wavegate remains committed to transforming the landscape of chronic pain treatment through cutting-edge innovation and patient-centered care.